Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:42 2024-07-04 am EDT 5-day change 1st Jan Change
243.4 CHF -1.06% Intraday chart for Roche Holding AG -2.80% -0.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Swiss Equities Close Higher as Inflation Eases; Roche Slumps MT
Market Update-Europe closes higher on optimism about US rates RE
ROCHE HOLDINGS AG : Gets a Sell rating from Goldman Sachs ZD
Market Update-European stock markets rise in absence of Wall Street RE
ROCHE HOLDINGS AG : UBS sticks Neutral ZD
Dax starts trading firmer - US interest rate policy in focus RE
ROCHE HOLDINGS AG : Sell rating from JP Morgan ZD
European shares advance on rate optimism; UK elections in focus RE
Roche: study in lung cancer fails and is discontinued CF
Roche to halt trial in latest setback for new cancer drug RE
Roche to Halt Lung Cancer Trial After Results Miss Goals DJ
Roche to Halt Trial of Combination Formulation for Non-small Cell Lung Cancer Treatment MT
Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer CI
ROCHE HOLDINGS AG : Berenberg sticks Neutral ZD
Goldman Sachs Lowers Price Target on Roche, Maintains Sell Recommendation MT
ROCHE HOLDINGS AG : Jefferies reiterates its Neutral rating ZD
ROCHE HOLDINGS AG : Goldman Sachs reiterates its Sell rating ZD
'HB': Sanofi plans to invest billions in Frankfurt DP
ROCHE HOLDINGS AG : Deutsche Bank remains Neutral ZD
BioPharma Credit to Provide Additional Funding to LumiraDx Amid Roche Deal MT
Swiss Market Index Closes Little Changed Amid Key European Inflation Data MT
Roche's Eye Therapy Vabysmo Gets EU Panel's Nod for Additional Indication MT
Roche: positive CHMP opinion for Vabysmo in OVR CF
Roche: positive CHMP opinion for PiaSky in HPN CF
Roche Gets EU Panel's Backing for Rare Blood Disorder Therapy MT
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
246 CHF
Average target price
276.4 CHF
Spread / Average Target
+12.37%
Consensus
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Swiss Equities Close Higher as Inflation Eases; Roche Slumps